A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design

mAbs

Volumn 6, Issue 4, 2014, Pages 1094-1102

  Davda, Jasmine P ^a,b   Dodds, Michael G ^a,b   Gibbs, Megan A ^a,b   Wisdom, Wendy ^a,b   Gibbs, John P ^a,b  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

Author keywords

Drug development; First in human; Meta analysis; Monoclonal antibody; Optimal design; Population pharmacokinetics

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; MONOCLONAL ANTIBODY;

ABSORPTION; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; RETROSPECTIVE STUDY; STUDY DESIGN; BIOLOGICAL MODEL; INTRAVENOUS DRUG ADMINISTRATION; STATISTICS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ANTIBODIES, MONOCLONAL; HUMANS; INJECTIONS, SUBCUTANEOUS; MODELS, BIOLOGICAL; STOCHASTIC PROCESSES;

EID: 84903744782     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.29095     Document Type: Article

References (24)

1. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84:548-58; PMID:18784655; http://dx.doi.org/10.1038/clpt.2008.170
2. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413-5; PMID:22531442; http://dx.doi.org/10.4161/mabs.19931
3. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93:2645-68; PMID:15389672; http://dx.doi.org/10.1002/jps.20178
4. Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 2007; 10:84-96; PMID:17265746
5. Brambell FW. The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet 1966; 2:1087-93; PMID:4162525; http://dx.doi.org/10.1016/S0140-6736(66)92190-8
6. Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J 2012; 14:296-302; PMID:22407289; http://dx.doi.org/10.1208/s12248-012-9340-y
7. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49:633-59; PMID:20818831; http://dx.doi.org/10.2165/11535960-000000000-00000
8. Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009; 49:1012-24; PMID:19620385; http://dx.doi.org/10.1177/ 0091270009337512
9. Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, Gupta M, Tang M, Allison DE, Lu D, et al. A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet 2012; 51:119-35; PMID:22257150; http://dx.doi.org/10.2165/ 11596370-000000000-00000
10. D'Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981; 9:739-56; PMID:7341758; http://dx.doi.org/10.1007/ BF01070904
11. Gibiansky L, Sutjandra L, Doshi S, Zheng J, Sohn W, Peterson MC, Jang GR, Chow AT, Pérez-Ruixo JJ. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet 2012; 51:247-60; PMID:22420579; http://dx.doi.org/10.2165/ 11598090-000000000-00000
12. Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, Hurh E, Gibbs MA. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 2011; 50:131-42; PMID:21241072; http://dx.doi.org/10.2165/11537430-000000000-00000
13. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 2011; 3:61-6; PMID:20962582; http://dx.doi.org/10.4161/ mabs.3.1.13799
14. Ling J, Zhou H, Jiao Q, Davis HM. Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 2009; 49:1382-402; PMID:19837907; http://dx.doi.org/10.1177/0091270009337134
15. Bumbaca D, Boswell CA, Fielder PJ, Khawli LA. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J 2012; 14:554-8; PMID:22610647; http://dx.doi.org/10.1208/s12248-012-9369- y
16. Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, Geng T, Lindquist K, Casas MG, Boustany LM, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem 2012; 287:11090-7; PMID:22294692; http://dx.doi.org/10.1074/jbc.M111.319764
17. Davda JP, Jain M, Batra SK, Gwilt PR, Robinson DH. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol 2008; 8:401-13; PMID:18279794; http://dx.doi.org/10.1016/j. intimp.2007.10.023
18. Ferl GZ, Wu AM, DiStefano JJ 3rd. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng 2005; 33:1640-52; PMID:16341929; http://dx.doi.org/10.1007/ s10439-005-7410-3
19. Byon W, Fletcher CV, Brundage RC. Impact of censoring data below an arbitrary quantification limit on structural model misspecification. J Pharmacokinet Pharmacodyn 2008; 35:101-16; PMID:17963024; http://dx.doi.org/10. 1007/s10928-007-9078-9
20. Gastonguay MR. Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: a review of methodology and 42 case studies, abstr 2229. Abstr Annu Meet Popul Approach Group Eur 2011; 20:http://www.page-meeting.org/?abstr=2229.
21. Larsen RJ, Marx ML. An Introduction to Mathematical Statistics. Upper Saddle River, NJ: Prentice-Hall, 1986.
22. Duffull SB, Mentré F, Aarons L. Optimal design of a population pharmacodynamic experiment for ivabradine. Pharm Res 2001; 18:83-9; PMID:11336357; http://dx.doi.org/10.1023/A:1011035028755
23. Duffull SB, Retout S, Mentré F. The use of simulated annealing for finding optimal population designs. Comput Methods Programs Biomed 2002; 69:25-35; PMID:12088590; http://dx.doi.org/10.1016/S0169-2607(01)00178-X
24. Hooker AC, Foracchia M, Dodds MG, Vicini P. An evaluation of population D-optimal designs via pharmacokinetic simulations. Ann Biomed Eng 2003; 31:98-111; PMID:12572660; http://dx.doi.org/10.1114/1.1533074